Do you want to read an article? Please log in or register.
Benralizumab In Severe Eosinophilic Asthma: A Real-Life Data From Türkiye
Asthma
Related content
RECOMMENDED
Asthma
Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Quarato CMI, Tondo P, Lacedonia D, Soccio P, Pescatore D, Baccellieri ML, Lepore G, Foschino Barbaro MP, Scioscia G
doi: 10.3390/jcm14062075
Asthma
ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up
Respir Med
Pini L, Caminati M, Maule M, Bagnasco D, Beghè B, Bondi B, Braido F, Cameli P, Caruso C, Crimi C, El Masri Y, Giordani J, Guarnieri G, Latorre M, Mastrototaro A, Menzella F, Micheletto C, Pini A, Piras S, Spanevello A, Vianello A, Visca D, Zappa M, Zurlo M, Paggiaro P, Blasi F, Canonica GW, Senna G, Benoni R, SANI study group
doi: 10.1016/j.rmed.2025.108198
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
RECOMMENDED
Asthma
Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Stolz D, Schuoler C, Charbonnier F, Bridevaux PO, Jandus P, Leuppi JD, Pavlov N, Piecyk A, Rothe T
doi: 10.2147/JAA.S495867
Asthma
Real-World Respiratory Effectiveness of mepolizumab in Severe Eosinophilic Asthma and Eosinophilic Granulomatosis with Polyangiitis
Respir Med
Zhu W, Chen K, Xiang Y, Shi J, Liang Y, Tong Y, Wang S, Zeng H, Zhang L, Ning X, Ye L, Jin M
doi: 10.1016/j.rmed.2025.108223
COMMENTED
Asthma
XALOC-1: Clinical remission over 2-years with benralizumab in severe eosinophilic asthma
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Chest
Pelaia G, Jackson DJ, Nair P, Emmanuel B, Tran TN, Menzies-Gow A, Watt M, Kayaniyil S, Boarino S, Nuevo J, Pardal M, Shavit A, Shih VH, Cohen D, Loureiro C, Padilla-Galo A
doi: 10.1016/j.chest.2025.04.011
Asthma
Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study
J Clin Med
Ausín P, Navarrete-Rouco ME, Carazo L, Sanchez-Trincado JL, Luzon E, Nuevo J, Santín M, Sánchez J, Padilla-Galo A
doi: 10.3390/jcm14093011
Asthma
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry
Respir Med
Harvey ES, Hamada Y, Hiles SA, Langton D, Thomas D, McDonald VM, Bardin P, Peters M, Reynolds PN, Upham JW, Blakey J, Bowler S, Chien J, Chung LP, Farah CS, Gillman A, Harrington J, Hew M, Jenkins C, Katelaris CH, Katsoulotos GP, Kritikos V, Lee J, Radhakrishna N, Sivakumaran P, Wark PAB, Gibson PG, Australian Mepolizumab Registry Investigators
doi: 10.1016/j.rmed.2025.108340
RECOMMENDED
Asthma
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Rimkunas A, Januskevicius A, Vasyle E, Palacionyte J, Kalinauskaite-Zukauske V, Miliauskas S, Malakauskas K
doi: 10.2147/JAA.S509001